Q1 2026 Earnings Forecast for Esperion Therapeutics, Inc. Issued By Zacks Research (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities research analysts at Zacks Research lowered their Q1 2026 earnings estimates for shares of Esperion Therapeutics in a report released on Monday, May 6th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings per share of $0.40 for the quarter, down from their prior estimate of $0.51. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.68) per share.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The business had revenue of $32.25 million for the quarter, compared to analyst estimates of $26.84 million. During the same quarter last year, the firm posted ($0.76) EPS.

A number of other equities research analysts have also recently commented on the stock. Needham & Company LLC restated a “buy” rating and issued a $8.00 price target on shares of Esperion Therapeutics in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research report on Monday, March 25th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $9.33.

Esperion Therapeutics Price Performance

Shares of NASDAQ:ESPR opened at $2.37 on Tuesday. The business’s 50-day moving average is $2.32 and its 200-day moving average is $2.07. Esperion Therapeutics has a 1 year low of $0.70 and a 1 year high of $3.40. The company has a market capitalization of $448.88 million, a price-to-earnings ratio of -1.12 and a beta of 0.89.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Spire Wealth Management increased its position in shares of Esperion Therapeutics by 69.2% during the fourth quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 7,267 shares in the last quarter. Private Portfolio Partners LLC purchased a new stake in shares of Esperion Therapeutics in the fourth quarter worth approximately $30,000. Herbst Group LLC bought a new position in shares of Esperion Therapeutics in the first quarter valued at approximately $28,000. Summit Financial LLC boosted its position in shares of Esperion Therapeutics by 66.8% during the first quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 10,355 shares during the last quarter. Finally, PSI Advisors LLC grew its holdings in Esperion Therapeutics by 161.5% during the fourth quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 10,500 shares in the last quarter. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.